PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP)

Historical Holders from Q3 2020 to Q4 2025

Type / Class
Equity / Common stock, par value $0.00001 per share
Symbol
PMVP on Nasdaq
Shares outstanding
52,942,731
Price per share
$1.25
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
37,492,718
Total reported value
$52,488,395
% of total 13F portfolios
0%
Share change
+2,812,009
Value change
+$4,772,987
Number of holders
63
Price from insider filings
$1.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ORBIMED ADVISORS LLC 9.4% $6,965,407 4,975,291 ORBIMED ADVISORS LLC 23 Oct 2025
TANG CAPITAL MANAGEMENT LLC 8.9% $6,702,907 4,720,357 TANG CAPITAL MANAGEMENT, LLC 16 Sep 2025
BML Investment Partners, L.P. 6.7% $3,744,019 3,466,684 BML Investment Partners, L.P. 31 Dec 2024
Sio Capital Management, LLC 5% -32% $3,691,167 -$1,538,387 2,636,548 -29% Sio Capital Management, LLC 30 Sep 2025
As of 30 Sep 2025, PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) has 63 institutional shareholders filing 13F forms. They hold 37,492,718 shares. of 52,942,731 outstanding shares (71%) .

Top 25 institutional shareholders own 68% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
ORBIMED ADVISORS LLC 11% 5,975,291 -7.7% 0.2% $8,365,407
BML Capital Management, LLC 10% 5,292,000 +5.8% 6.8% $7,408,800
TANG CAPITAL MANAGEMENT LLC 9% 4,785,201 0.26% $6,699,281
ArrowMark Colorado Holdings LLC 6.2% 3,301,341 +3.6% 0.09% $4,621,877
Sio Capital Management, LLC 5% 2,636,548 -29% 0.93% $3,691,167
Euclidean Capital LLC 5% 2,627,643 0% 1.5% $3,678,700
VANGUARD GROUP INC 4.1% 2,163,027 +0.44% 0% $3,028,239
ACADIAN ASSET MANAGEMENT LLC 3.9% 2,066,137 0% 0.01% $2,891,000
Stonepine Capital Management, LLC 2.6% 1,370,139 +62% 1.6% $1,918,195
BlackRock, Inc. 2.1% 1,104,140 -3.2% 0% $1,545,795
MARSHALL WACE, LLP 1.2% 612,626 0% $857,677
Aldebaran Capital, LLC 0.95% 504,128 -2.1% 0.65% $705,779
GEODE CAPITAL MANAGEMENT, LLC 0.82% 431,820 -0.2% 0% $604,698
TWO SIGMA ADVISERS, LP 0.79% 417,900 -14% 0% $585,060
JANE STREET GROUP, LLC 0.72% 382,050 0% $534,870
NORTHERN TRUST CORP 0.72% 380,813 +229% 0% $533,138
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.61% 320,653 +115% 0.01% $448,914
Walleye Capital LLC 0.53% 278,459 +258% 0% $389,843
TWO SIGMA INVESTMENTS, LP 0.51% 269,621 -7.5% 0% $377,469
RBF Capital, LLC 0.46% 245,561 0% 0.02% $343,785
Peapod Lane Capital LLC 0.38% 202,784 -55% 0.25% $283,908
BOOTHBAY FUND MANAGEMENT, LLC 0.38% 201,498 0.01% $282,097
CITADEL ADVISORS LLC 0.36% 193,153 -25% 0% $270,414
GOLDMAN SACHS GROUP INC 0.32% 170,802 +80% 0% $239,123
BANK OF AMERICA CORP /DE/ 0.31% 162,496 +458% 0% $227,495

Institutional Holders of PMV Pharmaceuticals, Inc. - Common stock, par value $0.00001 per share (PMVP) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q4 140,468 $175,585 +$21,720 $1.25 1
2025 Q3 37,492,718 $52,488,395 +$4,772,987 $1.40 63
2025 Q2 34,680,709 $36,758,763 -$2,911,770 $1.06 52
2025 Q1 37,320,031 $40,676,123 -$2,281,115 $1.09 54
2024 Q4 38,959,310 $58,833,270 -$767,790 $1.51 70
2024 Q3 39,023,873 $58,153,846 -$2,416,795 $1.49 73
2024 Q2 40,492,185 $65,594,864 -$3,771,661 $1.62 91
2024 Q1 42,725,320 $72,627,924 -$11,853,919 $1.70 96
2023 Q4 46,465,983 $144,025,863 -$52,160,467 $3.10 97
2023 Q3 54,236,025 $333,006,052 +$15,386,619 $6.14 103
2023 Q2 51,696,984 $323,689,509 +$3,281,155 $6.26 104
2023 Q1 51,513,177 $245,718,220 -$16,150,590 $4.77 111
2022 Q4 54,555,170 $474,625,571 -$38,255,414 $8.70 113
2022 Q3 58,187,852 $692,436,457 -$36,596,424 $11.90 116
2022 Q2 61,123,657 $870,921,498 +$53,476,878 $14.25 105
2022 Q1 55,249,345 $1,150,065,944 +$162,099,243 $20.82 98
2021 Q4 47,470,437 $1,096,597,184 +$15,190,740 $23.10 102
2021 Q3 43,990,444 $1,310,907,931 +$46,789,977 $29.80 91
2021 Q2 42,241,228 $1,442,956,792 +$80,038,413 $34.16 83
2021 Q1 39,915,363 $1,312,819,295 +$51,865,975 $32.89 81
2020 Q4 38,212,089 $2,335,342,669 +$185,049,476 $61.51 72
2020 Q3 31,212,908 $1,098,804,001 +$1,098,804,001 $35.50 51